Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on: October 10,2023 265

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on:October 10,2023 265

Rise in skin cancer cases underscores importance of early detection using machine learning

In a recent review published in theLifeJournal, a group of authors reviewed image-processing techniques in machine learning (ML) for skin cancer detection using clinical images, evaluating

Updated on: October 31,2023 15

Rise in skin cancer cases underscores importance of early detection using machine learning

In a recent review published in theLifeJournal, a group of authors reviewed image-processing techniques in machine learning (ML) for skin cancer detection using clinical images, evaluating

Updated on:October 31,2023 15

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on: December 20,2023 11

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on:December 20,2023 11

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on: October 24,2023 27

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on:October 24,2023 27

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on: December 19,2023 12

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on:December 19,2023 12

Helping blood cells regenerate after radiation therapy

Method boosts differentiation of stem cells into mature blood cell types, may help leukemia and lymphoma patients.Anne Trafton|MIT News OfficePublication Date:October 24, 2018 PRESS INQUIR

Updated on: October 11,2023 239

Helping blood cells regenerate after radiation therapy

Method boosts differentiation of stem cells into mature blood cell types, may help leukemia and lymphoma patients.Anne Trafton|MIT News OfficePublication Date:October 24, 2018 PRESS INQUIR

Updated on:October 11,2023 239

Researchers discover resistance to liver cancer treatment

byUniversity of Hawaii at ManoaCredit: Pixabay/CC0 Public DomainLiver cancer is the fourth deadliest cancer in Hawaiʻi, particularly affecting Native Hawaiian, Filipino and Japanese men. Patient

Updated on: October 31,2023 8

Researchers discover resistance to liver cancer treatment

byUniversity of Hawaii at ManoaCredit: Pixabay/CC0 Public DomainLiver cancer is the fourth deadliest cancer in Hawaiʻi, particularly affecting Native Hawaiian, Filipino and Japanese men. Patient

Updated on:October 31,2023 8

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023 13

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023 13

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on: October 11,2023 261

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression

Updated on:October 11,2023 261

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on: December 19,2023 12

Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations

byUniversity of Texas M. D. Anderson Cancer CenterBone marrow aspirate showing acute myeloid leukemia. Several blasts have Auer rods. Credit: WikipediaResearchers from The University of Texas MD

Updated on:December 19,2023 12

More Evidence Gene Therapy Might Cure Sickle Cell Disease

By Cara MurezHealthDay ReporterMONDAY, June 12, 2023 (HealthDay News) -- A clinical trial that’s attempting to discover a cure for sickle cell disease has found a new gene therapy to be safe and succe

Updated on: October 12,2023 176

More Evidence Gene Therapy Might Cure Sickle Cell Disease

By Cara MurezHealthDay ReporterMONDAY, June 12, 2023 (HealthDay News) -- A clinical trial that’s attempting to discover a cure for sickle cell disease has found a new gene therapy to be safe and succe

Updated on:October 12,2023 176

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on: October 24,2023 270

Long-Term Data Sustain Dabrafenib/Trametinib RFS Benefit in BRAF+ Melanoma

October 22, 2018Onclive TeamLong-term follow-up from the COMBI-AD trial continued to show a significant relapse-free survival advantage for patients with resected stage III BRAF-mutant melanoma treate

Updated on:October 24,2023 270